PROTACs: The Future of Leukemia Therapeutics

The fight to find effective, long-lasting treatments for cancer has led many researchers to consider protein degrading entities. Recent developments in PROteolysis TArgeting Chimeras (PROTACs) have signified their potential as possible cancer therapies. PROTACs are small molecule, protein degraders...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwar, Zubair, Ali, Muhammad Shahzad, Galvano, Antonio, Perez, Alessandro, La Mantia, Maria, Bukhari, Ihtisham, Swiatczak, Bartlomiej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479449/
https://www.ncbi.nlm.nih.gov/pubmed/36120561
http://dx.doi.org/10.3389/fcell.2022.851087
Descripción
Sumario:The fight to find effective, long-lasting treatments for cancer has led many researchers to consider protein degrading entities. Recent developments in PROteolysis TArgeting Chimeras (PROTACs) have signified their potential as possible cancer therapies. PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteasome pathway. This review mainly focuses on the general design and functioning of PROTACs as well as current advancements in the development of PROTACs as anticancer therapies. Particular emphasis is given to PROTACs designed against various types of Leukemia/Blood malignancies.

Ejemplares similares